Report of the IDEOM Meeting Adjacent to the GRAPPA 2024 Annual Meeting.

The International Dermatology Outcome Measures (IDEOM) organization presented updates on its patient-reported outcome measures (PROMs) for psoriasis (PsO), psoriatic arthritis (PsA), and other immune-mediated skin diseases at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 annual meeting. The Hidradenitis Suppurativa working group reported on the IDEOM Musculoskeletal Questionnaire (MSK-Q), a PROM for MSK manifestations of psoriatic disease. Advances in PsA screening included integrating the Psoriasis Epidemiology Screening Tool (PEST) and 12-item Psoriatic Arthritis Impact of Disease (PsAID-12) questionnaires into the Epic electronic health record system to streamline detection and management of emerging PsA cases. The Connective Tissue Disease working group discussed upcoming trials and tools for addressing significant unmet needs in cutaneous lupus erythematosus. Finally, the Patient Satisfaction working group provided updates on the 7-item Dermatology Treatment Satisfaction Instrument (DermSat-7) and DermSat-11 for clinical trials and real-world studies. The DermSat-7 has been validated in a multicenter study of patients with PsO, whereas the DermSat-11 is currently undergoing validation. IDEOM continues to work to significantly improve patient outcomes and satisfaction in dermatology.